The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.

Tukysa (tucatinib) may represent a new patient-friendly option as a first line maintenance treatment possibility for patients ...

Detailed price information for Actuate Therapeutics Inc (ACTU-Q) from The Globe and Mail including charting and trades.

Fiscal policy is the dominant market driver into 2025–26, but liquidity momentum is fading, raising volatility and downside ...

The Value Plus Strategy was down 0.10% in the fourth quarter, compared with the 3.26% gain for the Russell 2000® Value Index.

President Donald Trump has been back in office for almost a year. A new CNN/SSRS poll shows this year is seen poorly. What is ...

Public opinion on nearly every aspect of President Donald Trump’s first year back in the White House is negative, a new CNN ...

Six-year outcomes from the FROST trial show breast cancer cryoablation achieved low ipsilateral recurrence and high invasive ...

According to the Roku think-tank, AI's active devouring of the World Wide Web is going to make CTV a much more appealing ...

Only 16% of Republicans believe Trump has helped “a lot” to address the cost of living, the poll revealed. It is a stark drop ...

NYC Mayor Zohran Mamdani wants to emulate Sweden and Denmark's democratic socialism, but critics warn higher taxes would hit ...

The Detroit Tigers finished with an 87-75 record in the third year of Scott Harris and fifth year of A.J. Hinch, placing ...